Janssen EMEA - Articles and news items

Treating multiple myeloma: An interview with Janssen

Blog, Z Homepage promo / 17 May 2017 / Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA

We caught up with Janssen’s Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma…

EC approves Trevicta for the treatment of schizophrenia

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients…

CHMP adopts positive opinion of Trevicta for maintenance treatment of schizophrenia

Industry news / 5 April 2016 / Victoria White

If approved, this 3‑monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations…

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

Industry news / 26 October 2015 / Victoria White

If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time…

Janssen extends Blue Latitude contract

Industry news / 16 September 2015 / Victoria White

Blue Latitude has been reappointed to provide Janssen with strategic support and creative marketing services for their brand teams in the EMEA region…

Janssen submits MAA for daratumumab to EMA

Industry news / 10 September 2015 / Victoria White

Daratumumab is an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma…

EC approves Stelara for the treatment of plaque psoriasis in adolescent patients

Industry news / 3 July 2015 / Victoria White

The EC has approved Janssen’s Stelara for the treatment of moderate-to-severe plaque psoriasis in adolescent patients from the age of 12 years and older…


STELARA receives CHMP positive opinion for treatment of adolescents with moderate to severe psoriasis

Industry news / 27 May 2015 / Victoria White

The CHMP has recommended approval of STELARA for the treatment of moderate to severe plaque psoriasis in adolescent patients aged 12 and older…


EU Disease Lens brings visibility and insight into the most critical diseases

Industry news / 24 March 2015 / Victoria White

Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases…

Janssen Pharmaceuticals Logo

New findings from the Psoriasis Longitudinal Assessment and registry (PSOLAR) show persistency difference among biologic therapies

Industry news / 10 October 2014 / Janssen

Persistence of STELARA® (ustekinumab) significantly better than Anti-TNFs in treatment of Psoriasis according to observational study analysis…

Janssen Pharmaceuticals Logo


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...